Inflammatix has appointed João Fonseca as chief technology officer to oversee its molecular assay development and engineering teams as the firm advances its rapid tests for acute infections, sepsis, and COVID-19 risk stratification.
Since 2006, Fonseca has served as founder, CEO, and chief scientific officer of Biosurfit, a Lisbon, Portugal-based company whose blood tests diagnose multiple conditions at the point of care. The company's tests are broadly available throughout Europe.
Prior to Biosurfit, Fonseca was a professor in physics and experimental physics at the Technical University of Lisbon and a researcher at the University of Lisbon. He also founded a non-profit organization that works with patients and researchers to advance novel cancer treatments and research.